10-Q/A: Xencor Restates Financials Due to Accounting Errors, Royalty Treatment and Tax Misstatements Trigger Audit Committee Review

Xencor, Inc. restated its previously issued financial statements for fiscal year 2023 and the first three quarters of 2024 due to errors in accounting for a royalty transaction, research and development expenses, and state tax obligations, leading to a re-evaluation of internal controls.

Summary

• Xencor, Inc. has amended its Original Form 10-Q to restate its unaudited financial statements, financial data, and related disclosures for the three and nine months ended September 30, 2024.
• The restatement corrects errors related to the accounting treatment of a royalty transaction with OMERS Life Sciences, the unrecorded tax benefit related to research and development expenses, and an understatement of the Company's state tax obligations.
• The royalty transaction, initially accounted for as deferred income, should have been treated as debt.
• The impact on the consolidated balance sheet as of September 30, 2024, included an understatement of accounts receivable by $15.7 million, an overstatement of deferred income by $132.0 million, an understatement of debt by $154.9 million, and an overstatement of stockholders' equity by $7.2 million.
• The impact on the consolidated statement of income (loss) for the nine months ended September 30, 2024, included an understatement of revenue by $17.2 million and an understatement of interest expense by $25.3 million.
• The impact on the consolidated statement of cash flows for the nine months ended September 30, 2024, included an understatement of cash used in operating activities and cash provided by financing activities by $5.7 million each.
• The Company also identified an uncertain tax position of $6.2 million owed for the fiscal year ended December 31, 2023, related to the treatment of research and development expenses under Section 174 of the Code.
• Additionally, the Company understated its state income tax expense by approximately $2.1 million, net of federal benefit, for the year ended December 31, 2023.
• The impact on the consolidated balance sheet as of September 30, 2024, included an understatement of uncertain tax position payable by $8.3 million, an understatement of prepaid income tax by $0.6 million, and an overstatement of stockholders' equity by $7.7 million.
• Management has re-evaluated the effectiveness of the Company's internal controls over financial reporting as of September 30, 2024, and concluded that additional material weaknesses exist.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financials, the identification of material weaknesses in internal controls, and the potential for future financial misstatements. While the company is taking steps to remediate the issues, the uncertainty surrounding the impact on future financial reporting weighs negatively on the overall sentiment.

Negatives

• Xencor is restating its financial statements due to accounting errors, indicating potential weaknesses in its financial reporting processes.
• The incorrect accounting treatment of the royalty transaction with OMERS Life Sciences had a significant impact on the consolidated balance sheet and statement of income (loss).
• The understatement of revenue and interest expense for the nine months ended September 30, 2024, could mislead investors about the company's financial performance.
• The identification of an uncertain tax position and understatement of state income tax expense indicate potential non-compliance with tax regulations.
• The existence of additional material weaknesses in the Company's internal control over financial reporting raises concerns about the reliability of future financial reporting.

Risks

• The restatement of financial statements could negatively impact investor confidence and the company's stock price.
• The material weaknesses in internal control over financial reporting could lead to future financial misstatements and regulatory scrutiny.
• The company may incur additional costs to remediate the material weaknesses and improve its internal controls.
• The company's ability to accurately and timely report its financial condition and results of operations could be compromised.
• The company may face litigation or regulatory action related to the accounting errors and tax misstatements.

Future Outlook

Based upon the current operating plan, Xencor expects that its existing cash, cash equivalents, marketable securities, and certain potential milestone payments will fund its operating expenses and capital expenditure requirements into 2028.

Management Comments

• Management plans to (i) implement a more rigorous analysis of non-routine transactions, (ii) on highly technical and complex accounting transactions, we will improve our process to identify and select qualified third-party advisors, (iii) enhance our review of capabilities and work performed by the third-party advisors specifically related to the review of accounting guidance for complex non-routine transactions and ,(iv) enhance our review of capabilities and work performed by third-party advisors related to the review of tax advice and (v) on a quarterly basis, review income tax legislative changes and their impact to our financial statements with our tax expert.
• Notwithstanding these material weaknesses and after completion of additional procedures prior to the filing of this Form 10-Q/A, our management, including our Chief Executive Officer and Chief Financial Officer, has concluded that our financial statements in this Form 10-Q/A represent fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America.

Industry Context

The restatement highlights the complexities in accounting for royalty transactions and the importance of accurate tax reporting in the biopharmaceutical industry, where companies often rely on partnerships and licensing agreements for revenue generation.

Comparison to Industry Standards

• It is difficult to compare Xencor's restatement directly to industry standards without knowing the specific details of the royalty agreements and tax situations.
• However, restatements due to accounting errors are not uncommon in the pharmaceutical industry, particularly for companies with complex licensing and collaboration agreements.
• Companies like Amgen and Incyte, which partner with Xencor, have faced similar challenges in accurately accounting for revenue and expenses related to collaborations.
• The materiality of the errors and the resulting impact on financial statements will be closely scrutinized by investors and regulators.
• Xencor's response to the material weaknesses in internal control will be compared to best practices in the industry, such as those followed by companies like Regeneron and Biogen.

Legal Proceedings

• Merus N.V. filed a lawsuit against Xencor in August 2024, alleging patent infringement related to common light chain antibodies and heterodimeric antibodies.
• Merus seeks a judgment of patent infringement, an injunction, damages, a declaration of willful infringement, and a finding that the case is exceptional.
• Xencor filed a motion to dismiss the complaint, arguing that the activities are covered by the 35 U.S.C. 271(e)(1) safe harbor.
• Merus filed its response to Xencor's motion on October 31, 2024, and Xencor's deadline for replying is November 14, 2024.

Stakeholder Impact

• Shareholders may experience a decrease in stock value due to the restatement and identified material weaknesses.
• Employees may face uncertainty due to the potential for changes in internal controls and financial reporting processes.
• Customers and partners may be concerned about the reliability of Xencor's financial information and its impact on future collaborations.
• Suppliers and creditors may reassess their relationships with Xencor based on the company's financial stability and internal control environment.

Next Steps

• Management plans to implement a more rigorous analysis of non-routine transactions.
• Management will improve the process to identify and select qualified third-party advisors for highly technical and complex accounting transactions.
• Management will enhance the review of capabilities and work performed by third-party advisors specifically related to the review of accounting guidance for complex non-routine transactions.
• Management will enhance the review of capabilities and work performed by third-party advisors related to the review of tax advice.
• Management will review income tax legislative changes and their impact on financial statements with a tax expert on a quarterly basis.
• The company plans to initiate a Phase 1b/2a proof-of-concept study for plamotamab in rheumatoid arthritis (RA) in the first half of 2025.
• The Company plans to provide a clinical update around initiation of dose expansion cohorts during the first half of 2025 for XmAb819.
• The Company plans to provide a clinical update around initiation of dose expansion cohorts during the first half of 2025 for XmAb808.
• Through 2025, the company plans to advance the ongoing Phase 1 dose-escalation study toward target dose levels for XmAb541.
• The company anticipates a data readout from Phase 2 studies of vudalimab in patients with mCRPC in the first half of 2025.
• The company plans to evaluate the safety of vudalimab in combination with chemotherapy in a Phase 1b/2 study in patients with non-small cell lung cancer in the first half of 2025.
• The company anticipates initiating first-in-human studies during 2026 for XmAb TL1A x IL-23.

Key Dates

Keywords

restatement, financial statements, accounting errors, internal control, royalty transaction, research and development expenses, state tax obligations, material weaknesses, OMERS Life Sciences, Xencor